Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
about
How I report breast magnetic resonance imaging studies for breast cancer staging and screeningMolecular subtypes and imaging phenotypes of breast cancer.Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancersQuantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data setImaging Surveillance After Primary Breast Cancer Treatment.Associations between gene expression profiles of invasive breast cancer and Breast Imaging Reporting and Data System MRI lexicon.Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility studyA rim-enhanced mass with central cystic changes on MR imaging: how to distinguish breast cancer from inflammatory breast diseases?Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study.Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics StudyUsing computer-extracted image phenotypes from tumors on breast magnetic resonance imaging to predict breast cancer pathologic stage.Rim sign and histogram analysis of apparent diffusion coefficient values on diffusion-weighted MRI in triple-negative breast cancer: Comparison with ER-positive subtype.Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.Potential of Diffusion-Weighted Imaging in the Characterization of Malignant, Benign, and Healthy Breast Tissues and Molecular Subtypes of Breast Cancer.Diffusion weighted magnetic resonance imaging of the breast: protocol optimization, interpretation, and clinical applications.Analysis of factors influencing the degree of detectability on diffusion-weighted MRI and diffusion background signals in patients with invasive breast cancer.MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.Immunohistochemical Subtypes of Breast Cancer: Correlation with Clinicopathological and Radiological Factors.Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer compared to other subtypes of breast cancer.Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.Microstructural models for diffusion MRI in breast cancer and surrounding stroma: an ex vivo study.Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile.Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.Breast cancer molecular subtype classifier that incorporates MRI featuresCone-beam Breast Computed Tomography: CT Density Does Not Reflect Proliferation Potential and Receptor Expression of Breast Carcinoma.Multiparametric evaluation of preoperative MRI in early stage breast cancer: prognostic impact of peri-tumoral fat.Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes.Dynamic contrast enhanced-MRI in rectal cancer: Inter- and intraobserver reproducibility and the effect of slice selection on pharmacokinetic analysis.Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer.Whole-lesion apparent diffusion coefficient (ADC) metrics as a marker of breast tumour characterization-comparison between ADC value and ADC entropy.DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer.Potential Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer.Elastographic features of triple negative breast cancers.Diagnostic and prognostic values of contrast‑enhanced ultrasound combined with diffusion‑weighted magnetic resonance imaging in different subtypes of breast cancer.Can diffusion-weighted imaging predict tumor grade and expression of Ki-67 in breast cancer? A multicenter analysis.
P2860
Q26741706-C54E5B75-9A87-42AC-B42C-8CBB94B7FD6AQ28069885-A7A47A9E-9AA8-4F83-AA8B-09A5299F3D63Q30435824-47A1E0ED-C583-41CF-AA2F-ABDCBC4194FCQ31142731-8A252724-97FE-4A8F-9E65-04CAEBEA2237Q33763563-B0D3AC67-DFF1-4096-8A2D-7F3772FF1D57Q33899089-A678488A-11A8-4EBB-B812-39B4E5D132FAQ34409655-495E2648-6C38-4126-8600-6A3D09CB74F2Q35112066-CDDFE0D2-405D-4E11-B523-C8B9D2553396Q35815603-BC2509A4-56D7-49B4-8749-8FF80AB50BB5Q35850871-7DD7410B-6950-421D-A2B6-83C99595CF40Q35855936-CA3A73D6-748B-4CE5-B8C6-1938AD7D827FQ36380310-6185A74C-5E06-4789-A849-0DFF8E32D44AQ36612156-44070380-DE91-4997-93A1-6D90AA23FABCQ36925030-62B39133-40E6-426D-98AB-14902BEA0210Q37087591-428845B0-72D8-4ADC-98D8-F97542F2AD69Q37328026-C5A7CF8C-4EB8-4989-B58C-DD0E0DDF645FQ37348196-810BBCB2-5C28-4107-8792-C6FE12AF2F3BQ37425194-8678176D-AA6F-41FB-929D-8B9B1AF70A75Q37545811-C490F30D-F304-4D37-BC7C-94D473256FBDQ37558516-CB634B45-0D77-401E-98CF-570FC1E0C954Q37593722-D2C73548-FE25-4F40-8EA8-64B64BDBC3CDQ38074549-8A3C1231-40BB-41D9-A879-929920DBB121Q38250247-5FC6F818-FE72-4FAF-B2B2-2F65B4AA73C8Q38693206-EF60379F-647C-41CC-A40F-F46FB5495975Q38699875-C008F070-D7FF-44E4-8312-F74A6C6C599FQ39641098-C0F949A6-987B-47DD-B2ED-5FE8189E95F6Q40983403-3BEDC2FD-56F0-4573-B087-500A1CB31E18Q41276800-9035FD15-B6A3-4AD0-9096-3F87D6C85E01Q42113818-8DA8EF5A-E1B2-4C8B-ACAF-0CBC1E844A08Q46017323-0D88542A-E63A-45D1-9475-51F64C2A8031Q47095927-93A69DC3-CC62-494D-8687-0496EC5D3490Q47135880-553DC341-234A-416A-A8C4-B043E480AEA9Q47670339-9AD8D0A6-3BD1-4BD8-B1F1-3893EC5AB2ABQ47961966-0D54745F-87D1-4557-94EA-E1FAFF112A94Q50439039-D4200DFC-82A5-443C-B4C6-AA125F67EB2DQ55219187-E3C20B0A-4405-422D-94E7-6C34695F268CQ55286708-AC307AC4-9073-42D4-8109-2F16C3CB238D
P2860
Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Triple-negative invasive breas ...... other breast cancer subtypes.
@en
Triple-negative invasive breas ...... other breast cancer subtypes.
@nl
type
label
Triple-negative invasive breas ...... other breast cancer subtypes.
@en
Triple-negative invasive breas ...... other breast cancer subtypes.
@nl
prefLabel
Triple-negative invasive breas ...... other breast cancer subtypes.
@en
Triple-negative invasive breas ...... other breast cancer subtypes.
@nl
P2860
P50
P1433
P1476
Triple-negative invasive breas ...... other breast cancer subtypes.
@en
P2093
Ji Hyun Youk
P2860
P2888
P304
P356
10.1007/S00330-012-2425-2
P407
P577
2012-04-17T00:00:00Z